ALLERGAN SPECIALTY THERAPEUTICS INC
10-Q, EX-27.1, 2000-11-13
PHARMACEUTICAL PREPARATIONS
Previous: ALLERGAN SPECIALTY THERAPEUTICS INC, 10-Q, 2000-11-13
Next: SFSB HOLDING CO, 10QSB, 2000-11-13



<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JUL-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                              98
<SECURITIES>                                    59,936
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                64,123
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  64,123
<CURRENT-LIABILITIES>                            6,207
<BONDS>                                              0
                                0
                                          0
<COMMON>                                            34
<OTHER-SE>                                      57,882
<TOTAL-LIABILITY-AND-EQUITY>                    64,123
<SALES>                                              0
<TOTAL-REVENUES>                                   565
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                16,936
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (16,674)
<INCOME-TAX>                                       230
<INCOME-CONTINUING>                           (16,904)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (16,904)
<EPS-BASIC>                                     (5.16)
<EPS-DILUTED>                                   (5.16)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission